PDF(Pubmed)
Abstract：
GBM WHO CNS Grade 4 represents a major challenge for oncology due to its aggressive behavior. Conventional imaging has restrictions in detecting tumor recurrence. This prospective study aims to identify gene-based biomarkers in whole blood instead of isolating exosomes for the early detection of tumor recurrence. Blood samples (n = 33) were collected from seven GBM patients at time points before and after surgery as well as upon tumor recurrence. Four tumor tissue samples were assessed in parallel. Next-generation sequencing (NGS), including mRNA-seq and small RNA-seq, was used to analyze gene expression profiles in blood samples and tumor tissues. A novel filtering pipeline was invented to narrow down potential candidate genes. In total, between 6-93 mRNA and 1-19 small RNA candidates could be identified among the seven patients. The overlap of genes between the patients was minimal, indicating significant inter-individual variance among GBM patients. In summary, this prospective study supports the applicability of gene expression measurements in whole blood for the detection of tumor recurrence. It might provide an alternative to the challenging workflow of liquid biopsy after laborious exosome isolation from whole blood.
摘要：
GBMWHOCNS4级代表了肿瘤学的主要挑战，因为其攻击行为。常规成像在检测肿瘤复发方面存在限制。这项前瞻性研究旨在鉴定全血中基于基因的生物标志物，而不是分离外泌体以早期检测肿瘤复发。在手术前和手术后以及肿瘤复发后的时间点从7名GBM患者收集血液样品(n=33)。平行评估四个肿瘤组织样品。下一代测序（NGS），包括mRNA-seq和小RNA-seq，用于分析血液样本和肿瘤组织中的基因表达谱。发明了一种新的过滤管道来缩小潜在的候选基因。总的来说,在7例患者中可以鉴定出6-93个mRNA和1-19个小RNA候选物。患者之间的基因重叠很小，表明GBM患者之间存在显著的个体间差异。总之,这项前瞻性研究支持全血中基因表达检测在肿瘤复发检测中的适用性.在从全血中进行费力的外泌体分离后，它可能为液体活检的挑战性工作流程提供替代方案。
